Download PDF
Radiologie up2date 2024; 24(04): 361-375
DOI: 10.1055/a-2339-8448
Interventionelle Radiologie

Transarterielle Therapien bei HCC – ein Überblick anhand der aktuellen S3-Leitlinie

Transarterial therapies for HCC – an overview based on the current S3 guideline
Daniel Gnutzmann∗
1   Zentrum für Diagnostische und Interventionelle Radiologie, Klinikum Konstanz, Konstanz, Germany
,
Markus Juchems
1   Zentrum für Diagnostische und Interventionelle Radiologie, Klinikum Konstanz, Konstanz, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints All articles of this category

In den Leitlinien zum hepatozellulären Karzinom nehmen die transarteriellen Verfahren eine wichtige Rolle ein und sind im intermediären Stadium oft Mittel der Wahl. Die einzelnen Verfahren wie Radioembolisation und verschiedene Formen der Chemoembolisation werden in diesem Beitrag erläutert. Bei weltweit zunehmender Tumorlast ist trotz Fortschritten in der Systemtherapie von einer steigenden Bedeutung der Verfahren auszugehen.

Abstract

The current guidelines for diagnosis and therapy of hepatocellular carcinoma give an important role to transarterial therapies and are often the treatment of choice in the intermediate stage. Different modalities like radioembolization and different forms of chemoembolization with their specific indications and methods will be explained. With an increasing global tumor burden, it is likely that their importance increases in spite of advances in systemic therapy.

Kernaussagen

  • Beim intermediären HCC ist die transarterielle Therapie nach wie vor ein leitliniengerechter Standard.

  • Die Kenntnis der unterschiedlichen Therapieverfahren samt Vorteilen und Limitationen stärkt die Rolle des Radiologen in einem multidisziplinären Tumorboard.

  • Auch für sonst schwierig behandelbare Patienten bestehen z. B. mit biodegradierbaren Partikeln noch transarterielle Behandlungsoptionen.

  • Leitliniengerecht soll das Therapieansprechen nach transarterieller Behandlung nach mRECIST beurteilt werden.

  • Die technisch sorgfältige Ausführung und das klinische Verständnis sichern den Behandlungserfolg.

Schlüsselwörter

HCC - hepatozelluläres Karzinom - Chemoembolisation - Radioembolisation - SIRT - TARE - TACE

Keywords

HCC - hepatocellular carcinoma - chemoembolization - radioembolization - SIRT - TARE - TACE


Publication History

Article published online:
06 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
    CrossrefPubMedSearch in Google Scholar
  • 2 Bitzer M, Groß S, Albert J. et al. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0. Z Gastroenterol 2024; 62: e67-e161
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Llovet JM, Brú C, Bruix J. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Semin Liver Dis 1999; 19: 329-338
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Trevisani F, Vitale A, Kudo M. et al. Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal. J Hepatol 2024; 80: 661-669
    CrossrefPubMedSearch in Google Scholar
  • 5 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76: 681-693
    CrossrefPubMedSearch in Google Scholar
  • 6 Yamada R, Sato M, Kawabata M. et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401
    CrossrefPubMedSearch in Google Scholar
  • 7 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52
    CrossrefPubMedSearch in Google Scholar
  • 8 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264
    CrossrefPubMedSearch in Google Scholar
  • 9 Choi TW, Chung JW, Kim H-C. et al. Anatomic Variations of the Hepatic Artery in 5625 Patients. Radiol Cardiothorac Imaging 2021; 3: e210007
    CrossrefPubMedSearch in Google Scholar
  • 10 Llovet JM, Real MI, Montaña X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
    CrossrefPubMedSearch in Google Scholar
  • 11 Minici R, Ammendola M, Manti F. et al. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8–9. Front Pharmacol 2021; 12: 634087
    CrossrefPubMedSearch in Google Scholar
  • 12 Salem R, Johnson GE, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74: 2342-2352
    CrossrefPubMedSearch in Google Scholar
  • 13 Villalobos A, Pisanie JLd, Gandhi RT. et al. Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips. Semin Intervent Radiol 2024; 41: 63-78
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655
    CrossrefPubMedSearch in Google Scholar
  • 15 Lee MJ, Fanelli F, Haage P. et al. Patient safety in interventional radiology: a CIRSE IR checklist. Cardiovasc Intervent Radiol 2012; 35: 244-246
    CrossrefPubMedSearch in Google Scholar
  • 16 Gonella S, Clari M, Conti A. et al. Interventions to reduce arterial puncture-related pain: A systematic review and meta-analysis. Int J Nurs Stud 2022; 126: 104131
    CrossrefPubMedSearch in Google Scholar
  • 17 de Baere T, Ronot M, Chung JW. et al. Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE). Cardiovasc Intervent Radiol 2022; 45: 1430-1440
    CrossrefPubMedSearch in Google Scholar
  • 18 Brunskill N, Robinson J, Nocum D. et al. Exploring software navigation tools for liver tumour angiography: a scoping review. J Med Radiat Sci 2024; 71: 261-268
    CrossrefPubMedSearch in Google Scholar
  • 19 Miszczuk MA, Chapiro J, Geschwind J-FH. et al. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 2020; 13: 100742
    CrossrefPubMedSearch in Google Scholar
  • 20 Wu CH, Liang PC, Su TH. et al. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatol Int 2021; 15: 1247-1257
    CrossrefPubMedSearch in Google Scholar
  • 21 Vincenzi B, Di Maio M, Silletta M. et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015; 10: e0133488
    CrossrefPubMedSearch in Google Scholar
  • 22 Bai J, Huang M, Zhou J. et al. Development of a predictive nomogram for postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma. Sci Rep 2024; 14: 3303
    CrossrefPubMedSearch in Google Scholar
  • 23 Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. Exp Mol Med 2017; 49: e359
    CrossrefPubMedSearch in Google Scholar